Lilly halts enrollment in brain-cancer trial

Share this article:
Following the report of an external monitoring committee, Eli Lilly decided to halt enrollment in a late-stage clinical trial for cancer agent enzastaurin. Just two weeks ago, the company had told investors and analysts it was forging ahead with a phase III trial studying the compound in recurrent glioblastoma, an aggressive form of brain cancer. The trial was stopped after the committee’s report suggested enzastaurin would not improve progression-free survival over existing chemotherapy. Other enzastaurin trials are unaffected by the report, however. Lilly is enrolling patients in a Phase III trial testing enzastaurin for use as a maintenance therapy for the treatment of non-Hodgkin’s lymphoma. And several phase II studies continue across a variety of more common tumor types, including breast, colon, lung, ovarian and prostate cancers. Although the report was a minor setback, analysts called it the latest sign of softness in Lilly’s pipeline. In August, the FDA failed to approve diabetic retinopathy drug Arxxant (ruboxistaurin), subsequently asking for an additional phase III clinical trial which could take up to five years to complete. Lilly is appealing that decision. And last year Lilly said it was delaying development of anti-clotting drug called Prasugrel. Analysts had expected it to be on the market in 2007. Lilly said it expects to submit Prasugrel for FDA approval late next year.
Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...